NCT02740868View on ClinicalTrials.gov

Xenon-129 and Inert Fluorinated Gas Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Cystic FibrosisAsthma
Interventions
DRUG

Xenon-129 and Perfluoropropane (19F)

Xenon gas and perfluoropropane to be inhaled by research participants

DEVICE

Magnetic Resonance Imaging

Lung imaging will be performed for participants using MRI for all 3 arms

DEVICE

Lung Clearance Index

Lung clearance index (measure of lung health) will be performed for all participants of all 3 arms

Trial Locations (1)

M5G 1X8

RECRUITING

The Hospital for Sick Children, Toronto

All Listed Sponsors
lead

The Hospital for Sick Children

OTHER